← All articles
A morning table with a vial rack, a knee model, a blank medical console and a closed cabinet

A melanoma vaccine and a joint-tumor pill — plus 2 more stories

ResearchDigest · 4 storiesMedicine and treatment

4 stories this week: high-risk melanoma after surgery, a rare joint-lining tumor, and cardiac arrest outside hospital — a machine used before the hospital, and a community training program. Each note says who was studied and where the result stops.

In 1,137 adults with removed high-risk melanoma, a custom vaccine plus immunotherapy left 82.2% free of recurrence at two years

A laboratory bench with a pipette and a rack of clear unlabeled vials in cool window light

On 11 November 2026 the New England Journal of Medicine published a phase 3, double-blind trial. Intismeran autogene is an individualized neoantigen therapy designed to raise T-cell responses against mutations in that person's tumor. It is not an approved drug. Adults with completely resected stage IIB to IV cutaneous melanoma were assigned 2:1 to intismeran plus pembrolizumab, an immunotherapy everyone in the trial received, or to placebo plus the same pembrolizumab.

Of 1,137 people, 757 were assigned to intismeran plus pembrolizumab and 380 to placebo plus pembrolizumab. Median follow-up was 24.6 months. Recurrence-free survival at 24 months was 82.2% versus 70.0% (two-sided P<0.001). The piecewise hazard ratio was 0.99 (95% CI 0.66 to 1.49) before six months and 0.42 (95% CI 0.30 to 0.58) after six months. Distant-metastasis-free survival at 24 months was 88.5% versus 80.2% (P=0.002), with a piecewise hazard ratio of 1.01 (95% CI 0.58 to 1.79) before six months and 0.50 (95% CI 0.34 to 0.73) after.

Adverse events of grade 3 or higher occurred in 23.6% versus 20.3%. Eight people (1.1%) in the intismeran-pembrolizumab group died from an adverse event, and five of those deaths occurred before intismeran was given. The result applies to adults whose high-risk skin melanoma had already been fully removed. It is not an approval, overall survival is not in the journal abstract, and this is not a cell therapy. Merck Sharp and Dohme and Moderna funded the trial (NCT05933577).

The FDA approved a pill for adults with a symptomatic joint-lining tumor when surgery would cost function

An unlabeled knee model and wrist model on folded linen in an empty examination room

On 10 November 2026 the US Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor for which surgical resection may cause worsening functional limitation or severe morbidity.

Efficacy comes from MANEUVER (NCT05804045), a double-blind international trial that randomized people 2:1 to pimicotinib or placebo. Participants had confirmed symptomatic disease, measurable disease and at least one lesion of 2 cm or larger, and randomization was stratified by China versus other countries. The major endpoint, blinded independent review of overall response by RECIST version 1.1 at week 25, was 56% (95% CI 42 to 68) with pimicotinib and 3.2% (95% CI 0.1 to 17) with placebo. Median duration of response was not reached on pimicotinib; 32 responders (91%) still had a response at 6 months and 27 (77%) at 12 months. The notice also reports statistically significant gains at week 25 in active range of motion, worst pain and a physical-function score, without stating how large those gains were or how many people were randomized.

Adverse reactions in more than 20% of people were itching, rash, swelling of the face, swelling around the eyes, fatigue, nausea, headache and swelling of the limbs. Laboratory abnormalities in more than 30% included higher creatine phosphokinase, LDH, AST, lipase, cholesterol, amylase and ALT. The label warns about liver toxicity, harm to a fetus, and a rise in serum creatinine that does not mean kidney function has worsened. Review went through Project Orbis with Australia, Canada, Israel, Switzerland and the United Kingdom, with the European Medicines Agency as an observer. The drug also has fast-track and breakthrough designations. The comparison is with placebo in that selected adult group, not with older medicines.

Helicopter teams carrying a heart-lung machine were associated with more survivors among adults 50 and under

An empty stretcher and a compact medical console with a blank screen on a landing pad at dusk, a helicopter far in the background

On 7 November 2026 the New England Journal of Medicine published OnScene, a nationwide study in the Netherlands that was not randomized. It followed adults aged 50 or younger in refractory cardiac arrest outside hospital. Helicopter emergency teams equipped to start venoarterial extracorporeal membrane oxygenation before the hospital were compared with helicopter teams that could not.

Survival to hospital discharge was 57 of 144 (40%) with the equipped teams and 17 of 87 (20%) with conventional helicopter care (odds ratio 2.72, 95% CI 1.59 to 4.66, P=0.002). At six months a favorable neurologic outcome was recorded in 51 of 141 (36%) versus 11 of 85 (13%) (odds ratio 4.22, 95% CI 2.82 to 6.32).

The teams recorded 32 adverse events in the intervention group and 11 in the conventional group; the abstract does not say what they were. The paper says the machine was associated with higher survival, which matches a nonrandomized comparison of selected young adults in one country. It does not show what the same support would do for older adults or inside a randomized trial. The Dutch Ministry of Health funded the study (NCT04620070).

In North Carolina, 911 coaching and CPR classes did not raise good survival after cardiac arrest

An empty community hall with rows of wooden chairs and a plain closed cabinet on the wall

A second paper, published 8 November 2026 in the same journal, asked a different question and did not find a benefit. RACE-CARS was a registry-based cluster-randomized trial in North Carolina counties. Clusters were assigned 1:1 to usual care or to four changes together: training 911 call-takers to recognize cardiac arrest faster, training them to coach bystanders through chest compressions, community classes in those compressions, and wider use of automated external defibrillators by first responders or bystanders before the ambulance arrived. Outcomes came from the Cardiac Arrest Registry to Enhance Survival.

From 1 July 2022 through 30 June 2026, 28 clusters with 11,615 adults were assigned to the package and 27 clusters with 10,844 adults to usual care. Median age was 64.0 years and 36.7% were women. Survival to discharge with a good neurologic outcome, a Cerebral Performance Category of 1 or 2, was 9.0% (1,048 of 11,608) versus 9.4% (1,017 of 10,839). The adjusted odds ratio was 0.97 (95% CI 0.75 to 1.26, P=0.80).

The trial's conclusion is that the package did not leave a higher share of people with a good neurologic outcome than usual care. That is not a finding of harm, and it is not the Dutch helicopter result: one trial randomized a community program across adult cardiac arrests in one state, the other compared a machine, without randomization, in adults 50 and under. The National Heart, Lung, and Blood Institute funded RACE-CARS (NCT04660526).

This article is for information only and does not replace a consultation with a doctor. Nothing in it is a recommendation to start, stop or change treatment.

Sources

What this piece relies on

Cards

Articles in this section are educational and are not medical advice, a diagnosis, or a prescription. Consult a qualified professional before acting on anything you read here.

Read next